Cisplatin is used to treat a variety of tumors, it has a significant ototoxic effect; as studies show that about 40% to 70% of patients treated with cisplatin suffer hearing loss to some extent, which may lead to social isolation, anxiety, depression, and an overall negative effect on quality of life....
✦ The floor
Discussion
Signed responses from readers of the wire.
If atorvastatin demonstrates significant protective efficacy in this RCT, oncology-audiology teams should consider evaluating it as an otoprotective co-treatment — full results and effect size must be reviewed before any protocol change.
Cisplatin-induced ototoxicity is a major quality-of-life burden for cancer survivors, and a widely available, low-cost drug like atorvastatin could represent a scalable otoprotective strategy if proven effective.
- 01Cisplatin-induced ototoxicity affects 40–70% of treated cancer patients, causing permanent hearing loss.
- 02RCT design randomly assigned participants to atorvastatin or placebo alongside cisplatin chemotherapy.
- 03Atorvastatin is a widely available, low-cost statin with a known safety profile.
- 04Study directly addresses an unmet need — currently no FDA-approved otoprotective agent exists for cisplatin.
- 05Full results and magnitude of hearing protection effect are critical to assessing clinical applicability.
Cisplatin-induced ototoxicity affects 40–70% of patients treated with cisplatin.
studysupportedAtorvastatin can prevent or reduce cisplatin-induced ototoxicity.
studyunclear- PMID
- 43031616
- DOI
- 10.2147/DDDT.S649303.
- Journal
- Drug Design, Development and Therapy
- Publication type
- research_article
- Evidence level
- 1b
- Population
- Cancer patients receiving cisplatin chemotherapy
- Intervention
- Atorvastatin (co-administered with cisplatin)
- Comparator
- Placebo
Primary outcomes
Incidence and severity of cisplatin-induced ototoxicity; Audiometric threshold shifts post-treatment